Moderna may be facing regulatory uncertainty in the US for its infectious disease vaccine pipeline, but at least its clinical data is hitting the right notes. Today, the company revealed that its mRNA ...

Moderna has announced a new cost-cutting round as it tries to pare down its annual costs, with a new commitment to cut 10% off its headcount by the end of the year. The target is to reduce its ...

Moderna secured a $1.5 billion loan from Ares Management, structured in three tranches, to support financial flexibility and strategic goals. The company targets 10% revenue growth by 2026, leveraging ...

Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing self-sufficiency and efficiency in drug production. The expansion will create ...

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. Now, the study has to head back for a second season in the Northern Hemisphere after failing to find enough cases ...

Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Thursday before the bell. Here’s what investors should know. Moderna beat analysts’ revenue expectations by 10.7% last ...

Moderna may look appealing right now, given the company's high cash balance and extensive drug pipeline. However, as Moderna's cash burn dilemma persists, the company's net value will likely keep ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the morning session after the company announced positive preliminary data for its updated 2025-2026 COVID-19 vaccine, Spikevax®. The ...

In the age of artificial intelligence and organizational reinvention, Moderna is taking a big leap by reshaping the traditional corporate structure. The biotech giant recently merged its human ...

Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, announced Thursday that it will lay off about 10% of its workforce. Moderna CEO ...

Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees on ...

The Food and Drug Administration (FDA) granted full approval on Thursday to Moderna’s COVID-19 vaccine for children, making it the first COVID shot for kids aged 6 months to 11 years old that is no ...